Recent results of Janku et al. have shown the clinical significance of highlighting PIK3CA molecular status in BC patients, since tumors with PIK3CA mutations treated with PI3K/AKT/mTOR inhibitors showed a response rate of 30% matched to 10% in wild-type PIK3CA tumors; the response rate in wild-type PIK3CA tumors was comparable to previous reports (4%-11%) when patients were treated on phase I trials without molecular selection [58]. The gene discussed is AKT1; the disease is breast cancer.